1589 results about "Thiadiazoles" patented technology

The present invention provides a composition comprising the product prepared by hearing together: (a) a dispersant; and (b) a 1,3-dicarboxylic acid or 1,4-dicarboxylic acid of an aromatic compound, or a reactive equivalent thereof; and at least one of: (c) 2,5-dimercapto-1,3,4-thiadiazole or a hydrocarbyl-substituted 2,5-dimercapto-1,3,4-thiadiazole, or an oligomer thereof; (d) a borating agent; and (e) a phosphorus acid compound, or a reactive equivalent thereof, said heating being sufficient to provide a reaction product of (a), (b), and (c), (d), or (e), which is soluble in an oil of lubricating viscosity. The invention further provides a use for the composition.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

The present invention provides one kind of 1, 2, 3-thiobiazole-5-formamide compounds and their synthesis process and pesticide bioactivity screening. The screening system includes the determination of tobacco mosaic disease resisting activity, tobacco mosaic disease virus resistance inducing activity, and pesticidal and fungus-inhibiting activity. The related compounds are 1, 2, 3-thiobiazole-5-formamide derivatives with the general expression as shown, and include 7 hetero cycle containing 1, 2, 3-thiobiazole-5-formamide derivatives, 2 benzene ring containing 1, 2, 3-thiobiazole-5-formamide derivatives, and 2 aliphatic radical containing 1, 2, 3-thiobiazole-5-formamide derivatives.

PCT No. PCT / US96 / 11613 Sec. 371 Date Sep. 14, 1998 Sec. 102(e) Date Sep. 14, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97 / 03945 PCT Pub. Date Feb. 6, 1997Compounds of formula (I) wherein: R1 is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, (CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR6: W is alkynyl or 2 carbon atoms; R3 is H or R7; Z is C(O)R13, (CH2)0-1C(O)OR13, (CH2)0-1C(O)NR10R13, (CH2)0-1C(R8R8)OR8, -NHC(O)R7, (CH2)0-1NR10R13, NH[C(O)C(O)OR8], CH2NH[C(O)CNR10R13], CH2S(O)qR7, CH[S(O)qR7]2, dithiolane, (tetrazol-5-yl), thiazol-2-yl, [1,2,4]thiadiazol-5-yl, [1,3,4]oxadiazol-2-yl, imidazol-2-yl, oxazol-2-yl, or (3- or 5-oxadiazolyl[1,2,4]; R7 is -(CR4R5)qR11 or C1-6 alkyl wherein the R11 or C1-6 alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -NR8R10, -CO2R8, -O(CH2qR8, -NR8C(O)R8 or R12; or the pharmaceutically acceptable salts thereof.

This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPK / ERK Kinase (“MEK”) enzymes and pharmaceutical compositions and methods for their use in immunomodulation and in the treatment and alleviation of inflammation, and proliferative diseases such as cancer and restenosis.

The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

A compound of formula: (wherein X is O or S and R<1>, R<3>, R<4>, and R<5 >are disclosed herein) or a pharmaceutically acceptable salt thereof (a "Thiadiazolylpiperazine Compound"), pharmaceutical compositions comprising a Thiadiazolylpiperazine Compound, and methods for treating or preventing pain in a patient comprising administering to a patient in need thereof an effective amount of a Thiadiazolylpiperazine Compound are disclosed.

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

The invention discloses a screen phenol-containing thiadiazole type antioxygen antiwear additive and a preparation method thereof, wherein the chemical name of the additive is 2-(3,5-di-tert-butyl-4-hydroxy-benzyl)thio-5-alkylthio 1,3,4-thiadiazole. According to the preparation method, 2,5-dimercapto-1,3,4-thiadiazole is adopted as a raw material, the 2,5-dimercapto-1,3,4-thiadiazole and a halogenated alkane are subjected to a nucleophilic substitution reaction under a catalyst effect to generate monoalkyl thiadiazole, and the monoalkyl thiadiazole, formaldehyde and 2,6-di-tert-butylphenol are subjected to a condensation polymerization reaction under a catalyst effect to obtain 2-(3,5-di-tert-butyl-4-hydroxy-benzyl)thio-5-alkylthio 1,3,4-thiadiazole type lubricating oil multifunction additive, wherein the additive is characterized in that good oxidation resistance, extreme pressure property, wear resistance and corrosion resistance are provided for the lubricant with the additive, and the additive can be combined with other additives to provide good synergy effects, can be adopted to partly or completely replace ZDDP, and is applicable for internal combustion engine oils and industrial lubricating oils.

The invention relates to an organic semiconductor material containing naphthalene [1, 2-c: 5, 6-c] di [1, 2, 5] thiadiazole and application thereof, wherein the organic semiconductor material is prepared by reacting the halogenated derivatives with the monomer containing an aromatic group structure under the metal catalyst, wherein the halogenated derivatives are obtained by halogenating the naphthalene [1, 2-c: 5, 6-c] di [1, 2, 5] thiadiazole; the aromatic group is connected with a naphthalene [1, 2-c:5, 6-c] di [1, 2, 5] thiadiazole unit in a conjugate manner. The organic semiconductor material is characterized by containing 3, 7 substituted decorative[1, 2-c: 5, 6-c] di [1, 2, 5] thiadiazole chemical groups; as the naphthalene [1, 2-c:5, 6-c] di [1, 2, 5] thiadiazole has excellent electron-withdrawing ability and planarity, the organic semiconductor material can excellently adjust the photoelectric property, has excellent photoelectric performance, and is applied to the field of organic photoelectric components.

A method of regioselectively preparing a pyridine-containing compound is provided. In particular embodiments, the method includes reacting halogen-functionalized pyridal[2,1,3]thiadiazole with organotin-functionalized cyclopenta[2,1-b:3,4-b′]dithiophene or organotin-functionalized indaceno[1,2-b:5,6-b′]dithiophene. Also provided is a method of preparing a polymer. The method includes regioselectively preparing a monomer that includes a pyridal[2,1,3]thiadiazole unit; and reacting the monomer to produce a polymer that includes a regioregular conjugated backbone section, wherein the section includes a repeat unit containing the pyridal[2,1,3]thiadiazole unit. A polymer that includes a regioregular conjugated backbone section, and electronic devices that include the polymer, are also provided.

A sol solution containing poly(titanic acid) and a planar heterocyclic ligand is provided. Titanium dioxide (TiO2) particles are formed by aging the sol solution at a temperature below about 140° C. The particles have metallocene-like Ti-complexes comprising the heterocyclic ligand and can be substantially in the anatase phase. The heterocyclic ligands can be triazole, tetrazole, or thiadiazole. The sol solution may be prepared by aging a precursor solution. The precursor solution may contain the heterocyclic ligands and a precursor for poly(titanic acid). The precursor may be titanium alkoxide or titanium chloride. The sol solution may also contain at least one of an organic acid, a base, and a surfactant. The aged sol solution may form a colloidal dispersion of the TiO2 particles. A photo-catalytic and transparent film may be formed from the TiO2 particles by depositing a layer of the colloidal dispersion on a support.

A light emitting element includes a light emitting layer that is provided between an anode, a cathode, an anode, and a cathode, and the light emitting layer is configured to include the compound represented by Formula 1 below and the compound represented by Formula RH-1 below.(In Formula 1, A indicates an aryl group, an arylamino group, or triarylamine that may respectively independently include a hydrogen atom, an alkyl group, and a substituent.)(In Formula IRH-1, n indicates a natural number between 1 and 12, and R represents a substituent or a functional group, and indicates an aryl group or an arylamino group that may respectively independently include a hydrogen atom, an alkyl group, and a substituent.)

An antioxidizing and antiwear additive for lubricating oil is prepared from cryptophenol and 2-mercapto-5-alkylthio 1,3,4 thiadiazole through condensation reaction at 40-150 deg.C under existance of formaldehyde and acid catalyst.

The present invention is directed to ashless detergents comprising the products resulting from the reaction of a salicylic acid, organic group substituted salicylic acid, sulfonic acid or organic groups substituted sulfur acid with thiadiazole or organic group substituted thiadiazole or an alkyl primary or secondary amine, and to formulated lubricating oils containing said ashless detergents.

This invention is directed to a class of compounds (Formula I) including succinoyl amino pyrazoles, succinoyl amino thiadiazoles, succinoyl amino acid esters, succinoyl amino acid amides, succinoyl amino alcohols, succinoyl amino ketones, succinoyl amino hydantoins, succinoyl anilines, and succinoyl derivatives of privileged structures. The invention is also directed to a pharmaceutical formation comprising such compound in a pharmaceutically acceptable salt form or prodrug thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and / or synthesis, a method for inhibiting γ-secretase activity and a method for treating neurological disorders associated with β-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease.

The invention relates to thiadiazole derivatives which are shown as a formula I and have DPP-IV (dipeptidyl peptidase IV) inhibition activity, a preparation method of the thiadiazole derivatives and drug compositions of the thiadiazole derivatives, and application of the thiadiazole derivatives to treatment of diseases beneficial from DPP-IV inhibition, especially application to treatment of diabetes mellitus type 2. The thiadiazole derivatives provided by the invention have very good DPP-IV inhibition activity, have a very good in-vivo metabolic level and a very proper in-vivo half-life period and are expected to be used as proper DPP-IV inhibitor drugs.

The present invention provides a surface-treated steel sheet including a steel sheet; a plating layer provided on at least one of the surfaces of the steel sheet, the plating layer containing at least one metal selected from the group consisting of zinc and aluminum; a first layer film provided on the surface of the plating layer and containing (α) 1 to 2000 mg / m2 of silica in terms of SiO2, (β) a total of 1 to 1000 mg / m2 of phosphoric acid groups in terms of P, (γ) a total of 0.5 to 800 mg / m2 of at least one metal selected from the group consisting of Mg, Mn, and Al in terms of a metal element, and (δ) 0.1 to 50 mg / m2 of a tetravalent vanadium compound in terms of V; and a second layer film formed to a thickness of 0.1 to 5 μm on the first layer film and containing a resin (A) having at least one type of functional group selected from the group consisting of OH and COOH groups, and at least one rust-proofing additive (B) selected from the group consisting of (a) a phosphate, (b) Ca ion-exchanged silica, (c) a molybdate, (d) silicon oxide, and (e) at least one organic compound selected from the group consisting of triazoles, thiols, thiadiazoles, thiazoles, and thiurams. The surface-treated steel sheet has excellent corrosion resistance without containing hexavalent chromium in a coating, and also has excellent conductivity and coating appearance.

A corrosion-inhibiting composition for application to a metal substrate, such as aluminum or steel, and in connection with a paint, and the synthesis of the composition. The active inhibitor constituent of the composition can be selected from the group consisting of 2,5-dimercapto-1,3,4 thiadiazole (DMTD), 2,4-dimercapto-s-triazolo-[4,3-b]-1,3-4-thiadiazole, trithiocyanuric acid (TMT), and derivatives of DMTD and TMT, including various N— or S— and N, N—, S— and N—,S-substituted derivatives of DMTD, including salts of DMTD of the general formula: M(DMTD)n, where n=1,2 or 3, and M is a metal cation and preferably M=Zn(II), Bi(III), Co(II), Ni(II), Cd(II), Pb(II), Ag(I), Sb(III), Cu(II), Li(I), Ca(II), Sr(II), Mg(II), La(III), Ce(III), Pr(III), Al(III) or Zr(IV). DMTD, TMT, and their derivatives may also be combined with phosphates, molybdates, borates, silicates, tungstates, phosphotungstates, phosphomolybdates, cyanamides, carbonates, SiO2 and mixtures thereof.

A multifunctional dispersant useful in lubricating compositions is prepared by heating together (a) a dispersant and (b) 2,5-dimercapto-1,3,4-thiadiazole or a hydrocarbyl-substituted 2,5-dimercapto-1,3,4-thiadiazole which is substantially insoluble in a hydrocarbon oil of lubricating viscosity at 25° C., and further either (c) a borating agent or (d) an inorganic phosphorus compound, or both (c) and (d). The heating is sufficient to provide a reaction product of (a), (b), and (c) or (d) which is soluble in hydrocarbon oil at 25° C.

The present invention relates to 1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

The invention relates to a petroleum-engine oil composition and application thereof, and mainly aims to solve the problem of poor wear resistance of petroleum and engine oil existing in the prior art. The problem is well solved by adopting the technical scheme that the petroleum-engine oil composition comprises the following components in parts by weight: (a) 1-20 pars of a detergent, a dispersant or a mixture thereof, (b) 0.5-15 parts of an anti-oxygen wear-resistant agent, (c) 1-20 parts of a viscosity index modifier, (d) 0.01-5 parts of a pour point depressant, (e) 0.001-3 parts of an anti-foaming agent, and (f) 60-95 parts of base oil, wherein the anti-oxygen wear-resistant agent is selected from at least one of 2,6-di-tert-butyl-4-methylphenol, 2,6-di-tert-butyl mixed phenol, alkylated arylamine, zinc butyl octyl dithiophosphate, base zinc salt of dioctyl thiophosphate, di(octadecyl)-3,3-thiodipropionate, zinc(II)dibutyl dithiocarbamate, thiadiazole, molybdenum dithiocarbamate or molybdenum dialkyldithiophosphat. The petroleum-engine oil composition can be applied to industrial production of the petroleum-engine oil composition.

An antitumor agent comprising a thiadiazoline derivative represented by the general formula (I), or a pharmacologically acceptable salt thereof as an active ingredient: (wherein Z represents a sulfur atom and the like, R1 represents substituted or unsubstituted lower alkynyl and the like, R2 represents a hydrogen atom and the like, R3 represents substituted or unsubstituted lower alkyl and the like, and R4 represents substituted or unsubstituted aryl and the like), and the like are provided.

The invention relates to an ester type fire-resistant hydraulic fluid. The hydraulic fluid comprises the following raw materials by weight percent: 95-99% of base oil, 1.0-5.0% of diphenol propane, 0.005% of dimethylsilicone fluid or dimethylsilicone grease, 0.05% of tricresyl phosphate, 0.1% of benzotriazole, 100 parts per million (PPM) demulsifying agent T1001 or LZ5957 and 0.2-0.3% of triazole derivative, thiadiazole derivative, N-salicylidene ethylamine, N, N'-bis(salicylidene)ethylenediamine, N, N'-bis(salicylidene)propylene diamine or ethylenediamine tetraacetic acid. A preparation method of the ester type fire-resistant hydraulic fluid comprises the following steps of sufficiently and evenly stirring various materials at room temperature according to a formula, and then filtering. The ester type fire-resistant hydraulic fluid has the beneficial effects that the high temperature use performance of the product is greatly improved, the service life of a hydraulic system and the oil changing period of oils are prolonged, and the ester type fire-resistant hydraulic fluid has a good flame-retardant effect and is safe to use. The preparation method has the advantages that operation is convenient, technology and equipment are simple, energy consumption is low, cost is low, and the like.

The present invention relates to compositions comprising at least one triazole-containing species and at least one thiadiazole-containing species, which in embodiments are suitable for manual transmission oils.

The present invention provides a cefazedone sodium medicament powder injection composed of 100% of cefazedone sodium. The cefazedone sodium is prepared by a method as follows: (1) 7-ACA and 3, 5-dichloro pyridine acetic acid react with each other with the action of an anhydrating agent, a mixture after the reaction is post-processed to obtain an intermediate product I; (2) the intermediate product I and 2-mercapto-5-methyl-1, 3, 4-thiadiazoles react with each other with the protection of nitrogen at a temperature of 50 to 90 DEG C, a mixture after the reaction is purified to obtain a water solution which is added with an inorganic acid to regulate pH value to be equal to 1 to 3, a precipitation is extracted from the water solution and is post-processed to obtain cefazedone; (3) the cefazedone and sodium hydrogen carbonate react with each other in water to obtain a cefazedone sodium solid body after an aftertreatment. The powder injection has single component and perfect dissolution performance, the raw medicine has a short synthetic route, the aftertreatment of the intermediate product or final product are all simple, and the yield and purity of the whole reaction process are all high.